NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Assess Tolerability of the Trivalent Recombinant Vaccine in Individuals Aged 18 and Older Using the Vaccinees Perception of Injection Questionnaire

NCT06765187

CompletedN/A

Sponsor: Sanofi

Conditions: Influenza Immunization, Health Volunteers

Interventions: Trivalent Recombinant Influenza Vaccine

Countries: United States

This study aims to assess patient-reported experiences following trivalent recombinant influenza vaccine (RIV3) vaccination using the Vaccinees' Perception of Injection (VAPI) questionnaire, identify factors related to vaccine choice and future vaccination intentions in each case, and assess the cross-validity of VAPI, by establishing magnitude of correlations to EuroQol 5 Dimensions, 5 Levels (EQ-5D-5L) domains. Participants will need approximately 30 minutes to complete the self-administered online survey. Individuals will be recruited via a U.S. retail chain partner that offers the RIV3 vaccine as part of their routine influenza vaccination program

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: Yes

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Reside in the United States
* Be able to communicate and read fluently in English (U.S.)
* Have received the RIV3 vaccine within the past 21 days
* Have received the RIV3 vaccine in one of the 35 U.S. states or Washington, D.C., where the recruitment partner pharmacy operates
* Be able to provide explicit informed consent to participate in the study
* Be physically able to participate in a 30-min online survey using an internet-enabled device (e.g., computer, tablet, or smartphone)

Exclusion Criteria:

* Are unable to participate in the online survey
* Have received any other vaccine within the two weeks preceding the study vaccine (RIV3 vaccination); i.e., there must be at least a 2-week interval between the last vaccination and the time of enrollment/study execution
* Have received co-administered vaccinations on the same day as the study vaccine

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Locations (1)

Swiftwater, Pennsylvania, United States